eligibility_summary
Eligible: 18–75, consented, metastatic/unresectable pancreatic cancer with measurable disease, failed/none standard therapy (or relapse ≤6 mo post‑adjuvant), ECOG 0–1, life expectancy ≥12 wks, adequate organ/marrow, contraception and negative pregnancy test as required. Exclude: drug allergy, recent therapy/radiation/surgery or trial, other active cancer, active CNS mets, unresolved toxicities, ILD/pneumonitis, major infections (HIV, active HBV/HCV, TB), GI obstruction, recent CV/TE, pancreatitis risk, psych/substance issues, investigator decision.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06547736 tests three antibody–drug conjugates (ADCs)—SHR-A2102, SHR-A1904, and SHR-A1811—given as monotherapy or combined with HRS-4642 in advanced/metastatic pancreatic cancer. Drug types and mechanisms: • SHR-A2102, SHR-A1904, SHR-A1811: ADCs that bind tumor-associated surface antigens (antigens not specified), are internalized, and release a cytotoxic payload inside cancer cells (e.g., topo I or microtubule–targeting warheads) to induce apoptotic tumor cell death, targeted cytotoxic therapy. • HRS-4642: investigational small-molecule inhibitor of the RAS/MAPK oncogenic signaling axis (exact node not specified in the registry), intended to block proliferative signaling, targeted therapy. Targets/pathways: • Tumor cells expressing the respective ADC target antigens on the cell surface. • RAS–MAPK pathway (KRAS-driven signaling common in PDAC), including upstream RAS/SHP2 to downstream RAF–MEK–ERK signaling. Potential synergy: pathway blockade plus antigen-directed cytotoxicity.